الإحصائيات الأساسية
| LEI | 5493004823BTPRPZ8750 |
| CIK | 1516551 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Skye Bioscience, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience, |
|
| August 7, 2025 |
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update •Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025 •Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated •Independent Data Safety Monitoring Committee completed fourth unblinded review with no concerns raised; CBeyondTM study continues per protocol •New preclinical study highlights superior weight rebound profile of nimacimab compared to incretin therapy. |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 11, 2025 |
2025, addressed to the Securities and Exchange Commission June 11, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Skye Bioscience, Inc. under Item 4.01 of its Form 8-K dated June 11, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Skye Bioscience, Inc. contained therein. Very t |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience |
|
| May 8, 2025 |
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity •Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model •In vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonists •Expanded preclinical study data to be presented at ADA in June 2025 •Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025 SAN DIEGO, CA, May 8, 2025 - Skye Bioscience, Inc. |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 20, 2025 |
, by and between Skye Bioscience, Inc. and Executive Employment Agreement This Executive Employment Agreement (the “Agreement”), dated October 5, 2020, is between Emerald bioscience, inc. |
|
| March 20, 2025 |
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update •Enrollment completed in Phase 2a CBeyondTM trial of CB1 inhibitor, nimacimab, in obesity and overweight •Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed •Phase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy data •Cash runway projected through at least Q1 2027 SAN DIEGO, CA, March 20, 2025 - Skye Bioscience, Inc. |
|
| March 20, 2025 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material features of the common stock of Skye Bioscience, Inc. |
|
| March 20, 2025 |
by and between Skye Bioscience, Inc. and Chris Twitty Executive Employment Agreement This Executive Employment Agreement (the “Agreement”), dated November 11, 2022, is between Skye Bioscience, inc. |
|
| March 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Skye Bioscience, Inc. |
|
| March 20, 2025 |
Exhibit 10.1 SKYE BIOSCIENCE, INC. AMENDED AND RESTATED OMNIBUS INCENTIVE PLAN ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.01 Purpose. The purpose of the Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan (as may be further amended from time to time, the “Plan”) is to assist in attracting and retaining highly competent employees, executive officers, directors and Consultants to act |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosc |
|
| March 20, 2025 |
Skye Bioscience, Inc. Insider Trading Policy SKYE BIOSCIENCE, INC. Policy on Inside Information and Insider Trading A.Background/Purpose Under federal and state securities laws, it is illegal to engage in transactions in securities of Skye Bioscience, Inc. (the “Company”) while in possession of material, non-public information related to, affecting or regarding the Company, its subsidiaries or another company, including the Company’s partner |
|
| March 20, 2025 |
Exhibit 10.2 SKYE BIOSCIENCE, INC. AMENDED AND RESTATED 2024 INDUCEMENT EQUITY INCENTIVE PLAN ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.01.Purpose. The purpose of the Skye Bioscience, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan (as may be amended from time to time, the “Plan”) is to attract and retain highly competent Eligible Persons for positions of substantial responsibil |
|
| March 20, 2025 |
Subsidiaries of the Registrant Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Nemus July 17, 2012 California, USA Skye Bioscience, Inc. |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SKYE BIOSCIENCE, INC. (Exact name of Registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 11250 El Camino Real, Suite 100, San Diego, California 92130 (Add |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| February 26, 2025 |
Skye Bioscience, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan SKYE BIOSCIENCE, INC. AMENDED AND RESTATED 2024 INDUCEMENT EQUITY INCENTIVE PLAN ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.01.Purpose. The purpose of the Skye Bioscience, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan (as may be amended from time to time, the “Plan”) is to attract and retain highly competent Eligible Persons for positions of substantial responsibility by provid |
|
| December 23, 2024 |
▪[email protected] +1 (858) 410-0266 ▪11250 El Camino Real, Suite 100 San Diego, CA 92130 FOIA Confidential Treatment requested by Skye Bioscience, Inc. pursuant to 17 C.F.R. § 200.83 Certain confidential information identified by “[***]” has been omitted. December 23, 2024 Via Email Mr. Frank Wyman Ms. Bonnie Baynes U.S. Securities and Exchange Commission Division of Corporation Finance Off |
|
| December 19, 2024 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Skye Bioscience, Inc. shall be filed on behalf of each of the undersigned and that this Joint Filing Agreement shall be filed as an exhibit to such Schedule 13D. Dated: December 19, 2024 5AM Ventures VII, L.P. By: 5AM Partners VII, LLC its General P |
|
| December 19, 2024 |
Skye Bioscience Inc Stock Sale Plan for 5AM Venture Management LLC Exhibit 99.2 Skye Bioscience Inc Stock Sale Plan for 5AM Venture Management LLC This Stock Sale Plan (this “Plan”) is entered into this 17th day of December, 2024 (“Adoption Date”) between 5AM Partners II, LLC and 5AM Partners VII, LLC, in each case as represented by 5AM Venture Management LLC (the “Participant”) and Piper Sandler & Co. (the “Broker”). Recitals The Participant desires to establish |
|
| November 14, 2024 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-1 2 ex1.htm JOIINT ACQUISITION STATEMENT Skye Bioscience, Inc. Schedule 13G/A Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of th |
|
| November 14, 2024 |
SC 13G/A 1 sb-sc13ga093024.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Skye Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 83086J200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of t |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosci |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SKYE BIOSCIENCE, INC. (Exact name of Registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 11250 El Camino Real, Suite 100, San Diego, California 92130 (Add |
|
| November 7, 2024 |
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights SAN DIEGO, CA, November 7, 2024 - Skye Bioscience, Inc. |
|
| November 7, 2024 |
Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan SKYE BIOSCIENCE, INC. AMENDED AND RESTATED OMNIBUS INCENTIVE PLAN ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.01 Purpose. The purpose of the Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan (as may be further amended from time to time, the “Plan”) is to assist in attracting and retaining highly competent employees, executive officers, directors and Consultants to act as an incent |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Skye Bioscience, Inc. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 29, 2024 |
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board SAN DIEGO, California October 29, 2024 - Skye Bioscience, Inc. |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 22, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 23, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only ( |
|
| September 13, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only ( |
|
| September 4, 2024 |
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer SAN DIEGO, CA, September 3, 2024 - Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). “We are thrilled to welcome Dr. Puneet |
|
| September 4, 2024 |
between Skye Bioscience, Inc. and Dr. Puneet Arora ` Exhibit 10.1 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Executive Employment Agreement This Executive Employment Agreement (the “Agreement”), dated August 30, 2024, 2024 is between Skye Bioscience, inc. (the “Company” |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SKYE BIOSCIENCE, INC. (Exact name of Registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 11250 El Camino Real, Suite 100, San Diego, California 92130 (Add |
|
| August 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Skye Bioscience, Inc. |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Skye Bioscience, Inc. |
|
| August 9, 2024 |
and Stock Option Agreement under the 2024 Inducement Equity Incentive Plan Exhibit 10.2 NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTION AWARD – FOR US OPTIONEES SKYE BIOSCIENCE, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Skye Bioscience, Inc. (the "Company") hereby grants, pursuant to the provisions of the Company's 2024 Inducement Equity Incentive Plan, as amended from time to time (the "Plan"), to the Participant designated in this No |
|
| August 9, 2024 |
2024 Inducement Equity Incentive Plan Exhibit 10.1 SKYE BIOSCIENCE, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.01. Purpose. The purpose of the Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan (as may be amended from time to time, the “Plan”) is to attract and retain highly competent Eligible Persons for positions of substantial responsibility by providing an inducement material t |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience, |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SKYE BIOSCIENCE, INC. (Exact name of Registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 11250 El Camino Real, Suite 100, San Diego, California 92130 (Add |
|
| August 9, 2024 |
Exhibit 10.3 Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan Restricted Stock Unit Agreement Skye Bioscience, Inc., a Nevada corporation, (the “Company”), hereby grants Restricted Stock Units to the individual named below as the Participant, subject to the vesting requirements and other terms and conditions set forth in this Restricted Stock Unit Agreement, including the attached Terms |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 3, 2024 |
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors SAN DIEGO, CA, July 3, 2024 – Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeu |
|
| June 10, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| June 10, 2024 |
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued Phase 2 study of Nimacimab in obesity expected to start in Q3 2024 Cash runway extended into 2027 SAN DIEGO, June 10, 2024 – Skye Bioscience, Inc. |
|
| May 17, 2024 |
SKYE BIOSCIENCE, INC. Up to 4,000,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-279330 SKYE BIOSCIENCE, INC. Up to 4,000,000 Shares of Common Stock This prospectus relates to the possible resale from time to time by the selling securityholders named herein of up to 4,000,000 shares of common stock, $0.001 par value per share (the “Common Stock”) issued pursuant to that certain Securities Purchase Agreemen |
|
| May 15, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 May 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Dan Crawford Re: Skye Bioscience, Inc. Registration Statement on Form S-3 (File No. 333-279330) Request for Acceleration Dear Mr. Crawford: Pursuant to Rule 461 of the Gener |
|
| May 15, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 May 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Dan Crawford Re: Skye Bioscience, Inc. Registration Statement on Form S-3 (File No. 333-279331) Request for Acceleration Dear Mr. Crawford: Pursuant to Rule 461 of the Gener |
|
| May 15, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 May 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Dan Crawford Re: Skye Bioscience, Inc. Registration Statement on Form S-3 (File No. 333-279330) Request for Acceleration Dear Mr. Crawford: Pursuant to Rule 461 of the Gener |
|
| May 15, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 May 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Dan Crawford Re: Skye Bioscience, Inc. Registration Statement on Form S-3 (File No. 333-279331) Request for Acceleration Dear Mr. Crawford: Pursuant to Rule 461 of the Gener |
|
| May 10, 2024 |
Form of Indenture (including form of Debt Securities). Exhibit 4.5 SKYE BIOSCIENCE, INC. and [NAME OF TRUSTEE], as Trustee INDENTURE Dated as of , 202 CROSS-REFERENCE TABLE TIA Section Indenture Section 310 (a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.10 (b) 7.08; 7.10 (b)(1) 7.10 311 (a) N.A. (b) 7.11 (c) 7.11 312 (a) N.A. (b) 2.06 (c) 10.03 313 (a) 10.03 (b) 7.06 (b)(1) 7.08 (b)(2) N.A. (c) 7.06 (d) 7.06 314 (a) 4.08; 10.04 (b) N.A. (c)( |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Skye Bioscience, Inc. |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 29, 2024, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A.The Company and the Investors are executing and deliveri |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Skye Bioscience, Inc. |
|
| May 10, 2024 |
Equity Distribution Agreement, dated a Exhibit 1.2 Execution Version SKYE BIOSCIENCE, INC. EQUITY DISTRIBUTION AGREEMENT May 10, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Skye Bioscience, Inc., a company organized under the laws of Nevada (the “Company”), proposes to issue and sell from time to time through |
|
| April 24, 2024 |
As filed with the Securities and Exchange Commission on April 24, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 24, 2024 Registration No. |
|
| April 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Skye Bioscience, Inc. |
|
| April 10, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278286 SKYE BIOSCIENCE, INC. Up to 6,100,821 Shares of Common Stock Issuable Pursuant to an Agreement and Plan of Merger and Reorganization Up to 14,039,201 Shares of Common Stock Issuable Pursuant to Securities Purchase Agreements Up to 2,665,537 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 968,973 Shares o |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Skye Bioscience, Inc. (Exact name of registrant as specified in its charter) Nevada 45-0692882 (State of incorporation or organization) (I.R.S. Employer Identification No.) 11250 El Camino Real, Su |
|
| April 9, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 April 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Skye Bioscience, Inc. Registration Statement on Form S-1 (File No. 333-278286) Request for Acceleration Dear Ms. Hamill: Pursuant to Rule 461 of the Gener |
|
| April 9, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 April 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Skye Bioscience, Inc. Registration Statement on Form S-1 (File No. 333-278286) Request for Acceleration Dear Ms. Hamill: Pursuant to Rule 461 of the Gener |
|
| April 9, 2024 |
Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 April 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill Re: Skye Bioscience, Inc. Registration Statement on Form S-1 (File No. 333-278286) Request for Acceleration Dear Ms. Hamill: We hereby withdraw our prior requ |
|
| April 4, 2024 |
As filed with the Securities and Exchange Commission on April 4, 2024 As filed with the Securities and Exchange Commission on April 4, 2024 Registration No. |
|
| April 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| April 3, 2024 |
Exhibit 99.1 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) December 31, 2023 Pro Forma Adjustments As Adjusted December 31, 2023 ASSETS Current assets Cash $ 1,256,453 $ 84,680,741 (1)(2) $ 85,937,194 Restricted cash 9,080,202 9,080,202 Prepaid expenses 425,259 425,259 Other current assets 888,929 888,929 Total current assets 11,650,843 84,680,741 96,331, |
|
| March 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Skye Bioscience, Inc. |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 22, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: Skye Bioscience, Inc., a Nevada corporation; Aquila Merger Sub, Inc., a Delaware corporation; and Bird Rock Bio, Inc., a Delaware corporation Dated as of August 15, 2023 Table of Contents Page Section 1.......... DESCRIPTION OF TRANSACTION.................................. 2 1.1...... The Merger.............................. |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosc |
|
| March 22, 2024 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION OF SKYE BIOSCIENCE, INC. ARTICLE I NAME The name of the corporation is Skye Bioscience, Inc. (the “Corporation”). ARTICLE II REGISTERED OFFICE The Corporation may, from time to time, in the manner provided by law, change the registered agent and registered office within the State of Nevada. The Corporation may also maintain an office or offices for th |
|
| March 22, 2024 |
Subsidiaries of the Registrant Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Nemus July 17, 2012 California, USA Skye Bioscience, Inc. |
|
| March 22, 2024 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material features of the common stock of Skye Bioscience, Inc. |
|
| March 22, 2024 |
SKYE BIOSCIENCE, INC. COMPENSATION RECOUPMENT POLICY EFFECTIVE DATE: January 19, 2024 In the event of any required accounting restatement of the financial statements of Skye Bioscience, Inc. (the “Company”) due to the material noncompliance of the Company with any financial reporting requirement under the applicable U.S. federal securities laws, including any required accounting restatement to cor |
|
| March 13, 2024 |
, 2024, by and among Skye Bioscience, Inc. and the Investors named therein Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 11, 2024, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors signatory hereto. Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement, by and among the Compan |
|
| March 13, 2024 |
EX-99.H 2 tm248814d1ex99-h.htm EXHIBIT 99.H Exhibit H Lock-Up Agreement Skye Bioscience, Inc. March 11, 2024 Piper Sandler & Co. Oppenheimer & Co. Inc. As placement agents c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Oppenheimer & Co. Inc. 85 Broad Street, Floor 23 New York, New York 10004 Ladies and Gentlemen: This letter is being delivered to you |
|
| March 13, 2024 |
Amendment to Common Stock Purchase Warrants Exhibit 4.1 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS This Amendment to Common Stock Purchase Warrants (this “Amendment”), dated as of March 11, 2024, is by and between Skye Bioscience, Inc., a Nevada corporation (the “Company”), and 5AM Ventures VII, L.P. (the “5AM”). Capitalized terms used but not defined herein shall have the meaning ascribed to such term in the Purchase Agreement or Warrant |
|
| March 13, 2024 |
SKYE / Skye Bioscience, Inc. / 5AM Partners VII, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm248814d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Skye Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83086J200 (CUSIP Number) Paul A. Stone 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 9 |
|
| March 13, 2024 |
2024, by and among Skye Bioscience, Inc. and the Investors named therein Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 11, 2024, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Company and the Investors are executing and deliverin |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| March 4, 2024 |
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors San Diego, California, March 4, 2024 – Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with a focus on obesity and ocular indications, is |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| February 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| February 12, 2024 |
Exhibit 99.1 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2023 Pro Forma Adjustments As Adjusted September 30, 2023 ASSETS Current assets Cash and cash equivalents $ 5,126,245 $ 47,356,211 (1)(2) $ 52,482,456 Restricted cash 9,084,799 9,084,799 Prepaid expenses 207,226 207,226 Other current assets 867,919 867,919 Total current assets 15,286 |
|
| February 8, 2024 |
Joint Filing Agreement by and among the Reporting Persons Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Skye Bioscience, Inc. |
|
| February 8, 2024 |
SKYE / Skye Bioscience, Inc. / SPHERA FUNDS MANAGEMENT LTD. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Skye Bioscience, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 83086J200 (CUSIP Number) January 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 1 |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Skye Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 83086J200 (CUSIP Number) January 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 5, 2024 |
EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Altium Capital Management, LP SC 13G Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of th |
|
| January 31, 2024 |
SKYE / Skye Bioscience, Inc. / 5AM Partners VII, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm244665d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Skye Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83086J200 (CUSIP Number) Paul A. Stone 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA |
|
| January 31, 2024 |
EX-99.F 2 tm244665d1ex99f.htm EXHIBIT F Exhibit F Lock-Up Agreement Skye Bioscience, Inc. , 2024 Piper Sandler & Co. Oppenheimer & Co. Inc. As placement agents c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Oppenheimer & Co. Inc. 85 Broad Street, Floor 23 New York, New York 10004 Ladies and Gentlemen: This letter is being delivered to you in connecti |
|
| January 29, 2024 |
(incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 29, 2024, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors signatory hereto. Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement, by and among the Comp |
|
| January 29, 2024 |
Exhibit 4.1 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSEN |
|
| January 29, 2024 |
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye’s differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist SAN DIEGO, CALIFORNIA, January 29, 2024 – Skye Bioscience, Inc. (the Company) (OTCQB: SKYE), a clinical |
|
| January 29, 2024 |
projectsunrise-sparedac SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 29, 2024, by and among Skye Bioscience, Inc. |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2024 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SKYE BIOSCIENCE, INC. (Exact name of Registrant as specified in its charter) Nevada 45-0692882 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 11250 El Camino Real, Suite 100, San Diego, California 92130 (Add |
|
| December 22, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Skye Bioscience, Inc. |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| December 5, 2023 |
Exhibit 10.1 FINAL EXECUTION COPY Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (the “Agreement”) is entered into as of November 30, 2023 (the “Execution Date”) by and betwee |
|
| December 5, 2023 |
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa SAN DIEGO, CA, and JOHANNESBURG, SOUTH AFRICA, December 5, 2023 - Skye Bioscience, Inc. |
|
| December 5, 2023 |
, 2023, by and among Colliers Macaulay Nicolls Inc., Tab Labs Inc. and Avalite Sciences, Inc. Exhibit 10.2 OFFER TO SELL UNIT 104 – 9295 198TH STREET LANGLEY, BC THIS OFFER TO SELL made the 23 day of November, 2023. (“Offer” or “Agreement”) TO: COLLIERS MACAULAY NICOLLS INC. 200 Granville Street, 19th Floor Granville Square Vancouver, BC V6C 2R6 (hereinafter called the “Agent”) BETWEEN: TAB LABS INC. Unit D107, 19720 94A Avenue Langley, BC V1M 3B7 (hereinafter called the “Purchaser”) And: |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosci |
|
| November 14, 2023 |
(incorporated by reference to Exhibit 10.5 to our Q Exhibit 10.5 LOCK-UP AGREEMENT [●], 2023 Skye Bioscience, Inc. 1125 El Camino Real, Suite 100 San Diego, CA 92130 Attention: Punit Dhillon Email: Re: Lock-Up Agreement Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) is being delivered to Skye Bioscience, Inc., a Nevada corporation (the “Company”), in accordance with the [Agreement and Plan of Merger and Reorganization (the “M |
|
| November 7, 2023 |
Certificate of Amendment to Articles of Incorporation 11/06/2023 /s/ Punit Dhillon SKYE BIOSCIENCE, INC. CERTIFICATE OF AMENDMENT Exhibit A The Corporation shall have the authority to issue an aggregate of one hundred million, two hundred thousand (100,200,000) shares of capital stock, par value $0.001 per share, consisting of (a) one hundred million (100,000,000), shares of common stock, par value $0.001 per share (the “Common Stock”) and (b) two hu |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 17, 2023 |
Amendment No. 1 to Amended and Restated 2014 Omnibus Incentive Plan (incorporated by reference to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Skye Bioscience, Inc. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Skye Bioscience, Inc. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2023 |
Amendment No 1 to Amended and Restated 2014 Omnibus Incentive Plan AMENDMENT NO. 1 TO THE SKYE BIOSCIENCE, INC. AMENDED AND RESTATED 2014 OMNIBUS INCENTIVE PLAN The following Amendment No. 1 (the “Amendment”) to the Skye Bioscience, Inc. Amended and Restated 2014 Omnibus Incentive Plan (the “Plan”) was adopted by the Board of Directors (the “Board”) of Skye Bioscience, Inc. (the “Company”) on September 29, 2023 and approved by the Company’s stockholders on Septem |
|
| September 7, 2023 |
Skye Bioscience Reverse Stock Split to be Effective on September 8th Skye Bioscience Reverse Stock Split to be Effective on September 8th SAN DIEGO, CA, September 7, 2023 - Skye Bioscience, Inc. |
|
| September 7, 2023 |
Certificate of Correction to the Certificate of Change certificateofcorrection- FRANCISCO V. AGUILAR Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Correction NRS 78, 78A, 80, 81, 82, 84, 86, 87, 87A, 88, 88A, 89 and 92A (Only one document may be corrected per certificate.) TYPE OR PRINT - USE DARK INK ONLY - DO NOT HIGHLIGHT INSTRUCTIONS: 1. Enter the current name as on f |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 6, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| September 7, 2023 |
Certificate of Change, effective as of September certificateofchangerever BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov ABOVE SPACE IS FOR OFFICE USE ONLYUSE BLACK INK ONLY - DO NOT HIGHLIGHT Certificate of Change Pursuant to NRS 78.209 Certificate of Change filed Pursuant to NRS 78.209 For Nevada Profit Corporations 1. Name of corporation: 2. The board of dire |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| August 28, 2023 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Skye Bioscience, Inc. |
|
| August 28, 2023 |
SKYE / Skye Bioscience Inc / Versant Venture Capital III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. ) Skye Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83086J101 (CUSIP Number) August 1 |
|
| August 28, 2023 |
SKYE / Skye Bioscience Inc / 5AM Partners VII, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Skye Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 83086J101 (CUSIP Number) Rebecca Lucia 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 993-8565 (Name, Address and Tel |
|
| August 28, 2023 |
Exhibit D FORM OF LOCK-UP AGREEMENT August 15, 2023 Skye Bioscience, Inc. 11250 El Camino Real San Diego, CA 92130 Attention: Punit Dhillon Email: [email protected] Re: Lock-Up Agreement Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) is being delivered to Skye Bioscience, Inc., a Nevada corporation (the “Company”), in accordance with the [Securities Purchase Agreement (t |
|
| August 21, 2023 |
(incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2023, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors signatory hereto. Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement, by and among the Compa |
|
| August 21, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: SKYE BIOSCIENCE, INC., a Nevada corporation; AQUILA MERGER SUB, INC., a Delaware corporation; and BIRD ROCK BIO, INC., a Delaware corporation Dated as of August 15, 2023 -i- Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION .................................................................... 2 1.1 The Merger ..... |
|
| August 21, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2023, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A.The Company and the Investors are executing and deliverin |
|
| August 21, 2023 |
Exhibit 4.3 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSEN |
|
| August 21, 2023 |
Form of Indemnification Agreement Exhibit 10.4 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made and entered into on , 2023, by and between Skye Bioscience, Inc., a Nevada corporation (the “Company”), and (“Indemnitee”). WHEREAS, it is essential to the Company to retain and attract as directors and officers the most capable persons available; WHEREAS, the Company’s Bylaws authorizes the Company to ente |
|
| August 21, 2023 |
Corporate Communications – Q3 2023 Corporate Communications – Q3 2023 August 21, 2023 Skye Financing and Bird Rock Bio: Pre-recorded Call Script Bernie Hertel, Head of Corporate Communications Good morning. |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 21, 2023 |
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody Acquisition of Bird Rock Bio builds Skye’s position as a leading endocannabinoid system-focused pharmaceutical company •New capital funds anticipated Phase 2a glaucoma clinical trial •Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of CB1 signalin |
|
| August 21, 2023 |
Exhibit 4.1 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSEN |
|
| August 21, 2023 |
Exhibit 10.3 SKYE BIOSCIENCE, INC. SECURED NOTE AND WARRANT PURCHASE AGREEMENT THIS SECURED NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as of August 15, 2023 by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and MFDI, LLC, a California limited liability company (“Investor”). THE PARTIES HEREBY AGREE AS FOLLOWS: SECTION 1 ISSUANCE OF SECURED NOTE AND WARRA |
|
| August 21, 2023 |
Transaction & Overview Q3 2023 + skyebioscience.com • 2 FORWARD LOOKING STATEMENTS This presentation contains “forward-looking statements”, including statements regarding Skye Bioscience, Inc. (“Skye Bioscience and/or the Company”), within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation, whether written or ora |
|
| August 21, 2023 |
Exhibit 4.2 THIS SECURED CONVERTIBLE PROMISSORY NOTE AND ANY SECURITIES INTO WHICH THIS SECURED CONVERTIBLE PROMISSORY NOTE IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STAT |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience, |
|
| August 7, 2023 |
AMENDED AND RESTATED OFFICE LEASE by and between ROIC CALIFORNIA, LLC, a Delaware Limited Liability Company, as Landlord and SKYE BIOSCIENCE, INC. |
|
| May 12, 2023 |
Amendment to Executive Employment Agreement Amendment to Executive Employment Agreement This Amendment is made and entered into as of May 11, 2023, by and between Skye Bioscience, inc. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience |
|
| March 31, 2023 |
2022 Form of Warrant Issued to Former EHT Warrant Holders THE WARRANTS REPRESENTED HEREBY WILL BE VOID AND OF NO VALUE UNLESS EXERCISED WITHIN THE TIME LIMITS HEREIN PROVIDED. |
|
| March 31, 2023 |
Subsidiaries of the Registrant EX-21.1 4 subsidiariesoftheregistran.htm EX-21.1 Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Nemus July 17, 2012 California, USA Skye Bioscience, Inc. Skye Bioscience Pty Ltd. August 9, 2019 Australia Skye Bioscience, Inc. Emerald Health Therapeutics, Inc. July 31, 2007 British Columbia, Canada Skye Bioscience, Inc. Avalite Sciences, I |
|
| March 31, 2023 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Skye Bioscience, Inc. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosc |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorpor |
|
| March 20, 2023 |
SKYE / Skye Bioscience Inc / Emerald Health Sciences Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Skye Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29102Y101 (CUSIP Number) Emerald Health Sciences Inc. 10th Floor, 595 Howe St., Vancouver, BC V6C 2T5, Canada +1-778-868-1582 (Name, Address, and Telephone Number of P |
|
| February 23, 2023 |
Master Transaction Agreement, dated February MASTER TRANSACTION AGREEMENT This Master Transaction Agreement (this “Agreement”), dated as of February 16, 2023 (the “Effective Date”), is made by and between Skye Bioscience, Inc. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2023 |
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors San Diego, California, February 16, 2023 - Skye Bioscience, Inc. |
|
| February 15, 2023 |
AMENDMENT NO. 2 TO THE SHARE PURCHASE AGREEMENT THIS AMENDMENT is made as of February 9, 2023, BETWEEN: EMERALD HEALTH THERAPEUTICS, INC., a corporation incorporated under the Business Corporations Act (British Columbia), ("EHT") - and - C3 SOUVENIR HOLDING INC., a corporation incorporated under the Canada Business Corporations Act, ("Purchaser") - and - VERDÉLITE SCIENCES, INC., a corporation inc |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 15, 2023 |
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5. |
|
| January 27, 2023 |
EX-10.1 2 amendmentno1tothesharepurc.htm EX-10.1 AMENDMENT NO. 1 TO THE SHARE PURCHASE AGREEMENT THIS AMENDMENT is made as of January 26, 2023, BETWEEN: EMERALD HEALTH THERAPEUTICS, INC., a corporation incorporated under the Business Corporations Act (British Columbia), ("EHT") -and - C3 SOUVENIR HOLDING INC., a corporation incorporated under the Canada Business Corporations Act, ("Purchaser") -an |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2023 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 6, 2023 |
EX-10.1 2 amendmentno5tomultidrawcre.htm EX-10.1 AMENDMENT NO. 5 MULTI DRAW CREDIT AGREEMENT This Amendment (this “Amendment”) is made and entered into as of December 30, 2022, by and between Skye Bioscience, Inc., a corporation incorporated under the laws of the state of Nevada (the “Company”), and Emerald Health Sciences Inc., a corporation incorporated under the laws of British Columbia (the “L |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| December 19, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| December 19, 2022 |
PIGGYBACK REGISTRATION RIGHTS AGREEMENT December 14, 2022 This Piggyback Registration Rights Agreement (“Agreement”) is made and entered into as of December 14, 2022, by and between Skye Bioscience, Inc. |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| November 23, 2022 |
Amendment and Acknowledgement Agreement AMENDMENT AND acknowledgment agreement THIS AMENDMENT AND ACKNOWLEDGMENT AGREEMENT (this ?Agreement?) is dated as of November 17, 2022. |
|
| November 14, 2022 |
EX-10.3 3 sharepurchaseagreementrela.htm EX-10.3 Execution Copy SHARE PURCHASE AGREEMENT RELATING TO VERDELITE GROUP TABLE OF CONTENTS BACKGROUND 2 Article 1 INTERPRETATION 2 1.1 Definitions 2 1.2 Schedules and Disclosure Letter 3 Article 2 PURCHASE AND SALE OF THE PURCHASED SHARES 3 2.1 Purchase and Sale of the Purchased Shares 3 2.2 Deposit 3 2.3 Purchase Price 3 2.4 Payment of Purchase Price. 3 |
|
| November 14, 2022 |
NOTICE OF GRANT OF STOCK OPTION AWARD - FOR CANADIAN OPTIONEES SKYE BIOSCIENCE, INC. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosci |
|
| October 19, 2022 |
AMENDMENT NO. 3 TO ARRANGEMENT AGREEMENT BETWEEN SKYE BIOSCIENCE, INC. AND EMERALD HEALTH THERAPEUTICS, INC. October 14, 2022 AMENDMENT NO. 3 TO THE ARRANGEMENT AGREEMENT THIS AMENDMENT is made as of October 14, 2022, BETWEEN: EMERALD HEALTH THERAPEUTICS, INC., a corporation existing under the laws of the Province of British Columbia, (?EHT?) - and - SKYE BIOSCIENCE, INC., a corporation existing u |
|
| October 19, 2022 |
LOAN AGREEMENT THIS AGREEMENT (?Agreement?), is dated as of October 17, 2022 and is made by and between SKYE BIOSCIENCE, INC. |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 3, 2022 |
September 29, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Skye Bioscience, Inc.?s Form 8-K dated September 29, 2022, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01. Very |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2022 |
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc. |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| August 15, 2022 |
2022 Common Stock Warrant issued to Bear Creek Capital THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| August 15, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Skye Bioscience, Inc. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience, |
|
| August 15, 2022 |
Form of Stock Option Agreement under 2014 Omnibus Incentive Plan NOTICE OF GRANT OF NON-QUALIFIED STOCK OPTION AWARD ? FOR US OPTIONEES SKYE BIOSCIENCE, INC. |
|
| August 15, 2022 |
Form of Stock Option Agreement under 2014 Omnibus Incentive Plan (ISO) NOTICE OF GRANT OF INCENTIVE STOCK OPTION AWARD ? FOR US OPTIONEES SKYE BIOSCIENCE, INC. |
|
| July 21, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| July 21, 2022 |
AMENDMENT NO. 2 TO ARRANGEMENT AGREEMENT BETWEEN SKYE BIOSCIENCE, INC. AND EMERALD HEALTH THERAPEUTICS, INC. July 15, 2022 AMENDMENT NO. 2 TO THE ARRANGEMENT AGREEMENT THIS AMENDMENT is made as of July 15, 2022, BETWEEN: EMERALD HEALTH THERAPEUTICS, INC., a corporation existing under the laws of the Province of British Columbia, (?EHT?) - and - SKYE BIOSCIENCE, INC., a corporation existing under t |
|
| June 17, 2022 |
Execution Version AMENDMENT NO. 1 TO ARRANGEMENT AGREEMENT BETWEEN SKYE BIOSCIENCE, INC. AND EMERALD HEALTH THERAPEUTICS, INC. June 14, 2022 328972.00001/117641146.5 AMENDMENT NO. 1 TO THE ARRANGEMENT AGREEMENT THIS AMENDMENT is made as of June 14, 2022, BETWEEN: EMERALD HEALTH THERAPEUTICS, INC., a corporation existing under the laws of the Province of British Columbia, (?EHT?) - and - SKYE BIOSC |
|
| June 17, 2022 |
Letter of Mayer Hoffman McCann P.C. to the Securities and Exchange Commission, dated June 17, 2022 June 17, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Skye Bioscience, Inc.?s Form 8-K dated June 17, 2022, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01. Very truly your |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 18, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 23, 2022 |
SUPPORT AGREEMENT THIS AGREEMENT is effective as of May 11, 2022. BETWEEN: EMERALD HEALTH SCIENCES INC., a corporation existing under the laws of the Province of British Columbia, (the ?Securityholder?) AND: SKYE BIOSCIENCE, INC., a corporation existing under the laws of the State of Nevada, (?SKYE?). WHEREAS: A.Emerald Health Therapeutics, Inc. (the ?Company? or ?EHT?) and SKYE have entered into |
|
| May 23, 2022 |
Execution Version SUPPORT AGREEMENT THIS AGREEMENT is effective as of May 11, 2022. |
|
| May 12, 2022 |
Execution Version ARRANGEMENT AGREEMENT BETWEEN SKYE BIOSCIENCE, INC. AND EMERALD HEALTH THERAPEUTICS, INC. May 11, 2022 328972.00001/116443569.20 TABLE OF CONTENTS Article 1 INTERPRETATION 2 Section 1.1 Defined Terms 2 Section 1.2 Certain Rules of Interpretation 20 Article 2 THE ARRANGEMENT 21 Section 2.1 Arrangement 21 Section 2.2 Interim Order 21 Section 2.3 The EHT Meeting 22 Section 2.4 The E |
|
| May 12, 2022 |
SUPPORT AGREEMENT THIS AGREEMENT is dated as of [], 2022. BETWEEN: THE PERSON NAMED ON THE SIGNATURE PAGE HERETO, (the ?Securityholder?) AND: EMERALD HEALTH THERAPEUTICS, INC., a corporation existing under the laws of the Province of British Columbia, (?EHT?). WHEREAS: A.Skye Bioscience, Inc. (the ?Company? or ?SKYE?) and EHT have entered into a definitive arrangement agreement (the ?Definitive Ag |
|
| May 12, 2022 |
SUPPORT AGREEMENT THIS AGREEMENT is dated as of [], 2022. BETWEEN: THE PERSON NAMED ON THE SIGNATURE PAGE HERETO, (the ?Securityholder?) AND: SKYE BIOSCIENCE, INC., a corporation existing under the laws of the State of Nevada, (?SKYE?). WHEREAS: A.Emerald Health Therapeutics, Inc. (the ?Company? or ?EHT?) and SKYE have entered into a definitive arrangement agreement (the ?Definitive Agreement?) co |
|
| May 12, 2022 |
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics Arrangement is expected to fund Skye?s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies have demonstrated potential advantages of Skye?s unique, patent-protected therapeutic drug, SBI-100 Ophthalmic Emulsion, compared to the standard of care San Diego, California, May 12, 2022 - Skye Bioscience, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2022 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience |
|
| March 28, 2022 |
Amendment No. 3 to the Amended and Restated Multi-Draw Credit Agreement, dated AMENDMENT NO. 3 MULTI DRAW CREDIT AGREEMENT This Amendment (this ?Amendment?) is made and entered into as of September 15, 2021, by and between Skye Bioscience, Inc., a corporation incorporated under the laws of the state of Nevada (the ?Company?), and Emerald Health Sciences Inc., a corporation incorporated under the laws of British Columbia (the ?Lender?). The above parties are referred to colle |
|
| March 28, 2022 |
EX-10.5 2 formofskyerestrictedstocku.htm EX-10.5 Skye Bioscience, Inc. Skye Bioscience, Inc. 2014 Omnibus Incentive Plan, as amended Restricted Stock Unit Agreement Skye Bioscience, Inc., a Nevada corporation, (the “Company”), hereby grants Restricted Stock Units (to the individual named below as the Participant, subject to the vesting requirements and other terms and conditions set forth in this |
|
| March 28, 2022 |
Notice of Amendment to Stock Option Award Dear [] Skye Bioscience, Inc. (the ?Company?) has previously granted to you certain stock options to purchase the Company?s Common Stock, as set forth in the Appendix (the ?Options?) under the Company?s 2014 Omnibus Incentive Plan, as amended (the ?Plan?) and the applicable Notice of Grant of Stock Option Award and the Terms and Conditions of Stock Option |
|
| March 28, 2022 |
THE SYMBOL ?[****]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED RESTATED AND AMENDED LICENSE AGREEMENT THIS RESTATED AND AMENDED LICENSE AGREEMENT ("Agreement") is made as of this May 24, 2019 ("Effective Date") by and between the UNIVERSITY OF MISSISSIPPI, SCHOOL OF PHARMACY, an educational institution with a principal address at University, Mississippi 38677 ("UM"), and EMERALD BIOSCIENCE, INC. |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosc |
|
| March 28, 2022 |
Subsidiaries of the Registrant Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Nemus July 17, 2012 California, USA Skye Bioscience, Inc. Skye Bioscience Pty Ltd. August 9, 2019 Australia Skye Bioscience, Inc. |
|
| January 31, 2022 |
SKYE / Skye Bioscience Inc / Emerald Health Sciences Inc. - SC 13D/A Activist Investment SC 13D/A 1 skyesc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Skye Bioscience, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29102Y101 (CUSIP Number) Emerald Health Sciences Inc. Office 8262, 408 - 55 Water St., Vancouver, British Columbia, Canada V6B 1A1 + |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission F |
|
| December 20, 2021 |
EX-99.1 2 december152021pressrelease.htm EX-99.1 Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec 15, 2021 - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a biopharmaceutical company developing proprietary, synthetic canna |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Biosci |
|
| November 10, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-223895 PROSPECTUS SUPPLEMENT NO. 15 (To Prospectus Dated April 17, 2018) SKYE BIOSCIENCE, INC. Up to 140,694,163 Shares of Common Stock This prospectus supplement no. 15 supplements the prospectus dated April 17, 2018, relating to the resale by the selling shareholders identified in such prospectus of up to 140,694,163 shares of common stock of |
|
| October 15, 2021 |
EX-99.1 3 a211011skyexprxehbexsraxf.htm EX-99.1 Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program Exclusive sponsored research agreement with endocannabinoid research pioneers SAN DIEGO, CA, Oct 12, 2021 - Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat gl |
|
| October 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 15, 2021 |
THE SYMBOL ?[****]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EXCLUSIVE SPONSORED RESEARCH AGREEMENT This Exclusive Sponsored Research Agreement (?Agreement?) is dated as of October 11, 2021 (the ?Effective Date?) by and between Skye Bioscience Inc. |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 6, 2021 |
Executive Employment Agreement This Executive Employment Agreement (the ?Agreement?), dated October 4, 2021, is between Skye Bioscience, inc. |
|
| October 6, 2021 |
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer SAN DIEGO, CA, October 5, 2021 - Skye Bioscience, Inc. |
|
| September 30, 2021 |
Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering SAN DIEGO, CA, September 29, 2021 - Skye Bioscience, Inc. (OTCQB: SKYE) (?SKYE? or the ?Company?), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced the closing of its previously announced registered |
|
| September 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission |
|
| September 28, 2021 |
Form of Placement Agent Warrant EXHIBIT 4.3 PURSUANT TO THE TERMS OF SECTION 2(A) OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNT SET FORTH ON THE FACE HEREOF. PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC. Warrant Shares: [] Issue Date: [], 2021 Initial Exercise Date: [], 2021 |
|
| September 28, 2021 |
EX-4.1 2 skyeex41.htm SERIES A WARRANT EXHIBIT 4.1 PURSUANT TO THE TERMS OF SECTION 2(A) OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNT SET FORTH ON THE FACE HEREOF. SERIES A COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC. Warrant Shares: [] Issue Date:, 2021 In |
|
| September 28, 2021 |
Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 27, 2021, between Skye Bioscience, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| September 28, 2021 |
EX-10.2 7 skyeex102.htm LOCK-UP AGREEMENT EXHIBIT 10.2 LOCK-UP AGREEMENT , 2021 Skye Bioscience, Inc. Re: Securities Purchase Agreement, dated as of September , 2021 (the “Purchase Agreement”), between Skye Bioscience, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this |
|
| September 28, 2021 |
EXHIBIT 4.2 PURSUANT TO THE TERMS OF SECTION 2(A) OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNT SET FORTH ON THE FACE HEREOF. PRE-FUNDED COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC. Warrant Shares: [] Issue Date:, 2021 Initial Exercise Date: [], 2021 THIS PR |
|
| September 28, 2021 |
Skye Bioscience Announces $7.0 Million Registered Direct Offering EX-99.1 8 skyeex991.htm PRESS RELEASE EXHIBIT 99.1 Skye Bioscience Announces $7.0 Million Registered Direct Offering SAN DIEGO, CA, September 27, 2021 - Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced that it ha |
|
| September 28, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258243 PROSPECTUS SUPPLEMENT (To Prospectus dated August 9, 2021) SKYE BIOSCIENCE, INC. 58,111,112 Shares of Common Stock Pre-Funded Warrants to Purchase up to 19,666,667 Shares of Common Stock Series A Warrants to Purchase up to 77,777,779 Shares of Common Stock Placement Agent Warrants to Purchase up to 5,444,445 Shares of Common Stock We are |
|
| September 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission |
|
| September 15, 2021 | ||
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience, |
|
| August 6, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-223895 PROSPECTUS SUPPLEMENT NO. 14 (To Prospectus Dated April 17, 2018) SKYE BIOSCIENCE, INC. Up to 140,694,163 Shares of Common Stock This prospectus supplement no. 14 supplements the prospectus dated April 17, 2018, relating to the resale by the selling shareholders identified in such prospectus of up to 140,694,163 shares of common stock of |
|
| August 6, 2021 |
THE SYMBOL ?[****]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED COLLABORATIVE RESEARCH AGREEMENT THIS COLLABORATIVE RESEARCH AGREEMENT (this ?Agreement?) effective as of April 30, 2021 (the ?Effective Date?), is entered into between SKYE BIOSCIENCE INC. |
|
| August 6, 2021 |
1.6 Sublessee's Share of Opera ng Expenses: percent ( 25 %) ("Sublessee's Share"). In the event that that size of the Premises 1. Basic Provisions ("Basic Provisions"). 1.1 Par es: This Sublease ("Sublease"), dated for reference purposes only April 30, 2021 , is made by and between Emerald Health Pharmaceuticals Inc. ("Sublessor") and Skye Bioscience ("Sublessee"), (collec vely the "Par es", or in |
|
| August 5, 2021 |
SKYE BIOSCIENCE, INC. 5910 Pacific Center Boulevard Suite 320 San Diego, CA 92121 SKYE BIOSCIENCE, INC. 5910 Pacific Center Boulevard Suite 320 San Diego, CA 92121 August 5, 2021 SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Ms. Lauren Hamill Re: Skye Bioscience, Inc. Registration Statement on Form S-3 Filed July 29, 2021 File No. 333-258243 Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| July 29, 2021 |
As filed with the Securities and Exchange Commission on July 28, 2021 As filed with the Securities and Exchange Commission on July 28, 2021 Registration No. |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 22, 2021 SKYE BIOSCIENCE, INC. |
|
| July 26, 2021 |
Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors EXHIBIT 99.1 Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors SAN DIEGO, CA, July 25, 2021 - Skye Bioscience, Inc. (OTCQB: SKYE) (?SKYE? or the ?Company?), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., as an independe |
|
| July 22, 2021 |
EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File |
|
| July 22, 2021 |
EXHIBIT 10.1 SKYE BIOSCIENCE, INC. July 21, 2021 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Skye Bioscience, Inc. (the ?Company?) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Common Stock?), issued to you on Augu |
|
| May 7, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-223895 PROSPECTUS SUPPLEMENT NO. 13 (To Prospectus Dated April 17, 2018) SKYE BIOSCIENCE, INC. Up to 140,694,163 Shares of Common Stock This prospectus supplement no. 13 supplements the prospectus dated April 17, 2018, relating to the resale by the selling shareholders identified in such prospectus of up to 140,694,163 shares of common stock of |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience |
|
| May 7, 2021 |
Amendment No. 2 to Multi-Draw Credit Agreement AMENDMENT NO. 2 MULTI DRAW CREDIT AGREEMENT THIS AMENDMENT AGREEMENT, dated for reference March 29, 2021, is made BETWEEN: SKYE BIOSCIENCE, INC., a corporation incorporated under the laws of Nevada (the ?Company?) AND: EMERALD HEALTH SCIENCES INC., a corporation incorporated under the laws of British Columbia (the ?Lender?) WHEREAS: A. The Lender and the Company entered into a Multi Draw Credit Ag |
|
| March 2, 2021 |
EXHIBIT 10.63 COLLABORATIVE RESEARCH AGREEMENT THIS COLLABORATIVE RESEARCH AGREEMENT (this ?Agreement?) effective as of January 2021 (the ?Effective Date?), is entered into between EMERALD BIOSCIENCE INC. (?EMBI?), with a place of business at 5910 Pacific Center Blvd., #320 San Diego, CA, 92121, United States and EMERALD HEALTH BIOTECHNOLOGY ESPA?A, S.L. a limited liability company incorporated un |
|
| March 2, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-223895 PROSPECTUS SUPPLEMENT NO. 12 (To Prospectus Dated April 17, 2018) SKYE BIOSCIENCE, INC. Up to 140,694,163 Shares of Common Stock This prospectus supplement no. 12 supplements the prospectus dated April 17, 2018, relating to the resale by the selling shareholders identified in such prospectus of up to 140,694,163 shares of common stock of |
|
| March 2, 2021 |
EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS of SKYE BIOSCIENCE, INC. (a Nevada corporation) ARTICLE I OFFICES Section 1.1 Principal Office. The principal office and place of business of Skye Bioscience, Inc., a Nevada corporation (the ?Corporation?), shall be established from time to time by resolution of the board of directors of the Corporation (the ?Board?). Section 1.2 Other Offices. Other offices |
|
| March 2, 2021 |
Amended and Restated Articles of Incorporation (1) EXHIBIT 3.1 |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55136 Skye Bioscience, Inc. (Exact |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Skye Bioscience, Inc. f/k/a Emerald Bioscience, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti |
|
| February 3, 2021 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 28, 2021 SKYE BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 19, 2021 |
Amendment to Articles of Incorporation. EXHIBIT 3.1 AMENDMENT TO ARTICLES OF INCORPORATION 1. Name of corporation: Skye Bioscience, Inc. |
